Details of the Drug

General Information of Drug (ID: DMROZUA)

Drug Name

Pyroglutamic Acid

Synonyms

DL-Pyroglutamic acid; 149-87-1; 5-Oxopyrrolidine-2-carboxylic acid; 2-Pyrrolidone-5-carboxylic acid; DL-Proline, 5-oxo-; 5-OXOPROLINE; 5-Oxo-DL-proline; Pyroglutamate; D-(+)-Pyroglutamic Acid; DL-Glutamic Acid Lactam; Pyrrolidonecarboxylic acid; CHEBI:16010; ODHCTXKNWHHXJC-UHFFFAOYSA-N; MFCD00064322; 5-oxoprolinate; DL-Pidolic acid; (+)-Pyroglutamic acid; 5-OXO-2-PYRROLIDINECARBOXYLIC ACID; D-Pyroglutamate; (+)-2-Pyrrolidone-5-carboxylic acid; DL-5-Oxoproline; (D-5-Oxo-2-pyrrolidinecarboxylic acid); Proline,5-oxo-; 5-Oxoproline #

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

129.11

Logarithm of the Partition Coefficient (xlogp)

-0.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Elimination: 30% of an absorbed oral administration was excreted unchanged in the urine and the remainder converted to urea (in a dog study) []
Half-life: The concentration or amount of drug in body reduced by one-half in 9 months [2]
Metabolism: The drug is metabolized via the glutaminyl cyclase [3]

Chemical Identifiers

Formula: C5H7NO3
IUPAC Name: (2S)-5-oxopyrrolidine-2-carboxylic acid
Canonical SMILES: C1CC(=O)N[C@@H]1C(=O)O
InChI: InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1
InChIKey: ODHCTXKNWHHXJC-VKHMYHEASA-N

Cross-matching ID

PubChem CID: 7405
ChEBI ID: CHEBI:18183
CAS Number: 98-79-3
DrugBank ID: DB03088
TTD ID: D0U7QA
VARIDT ID: DR00293

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiogenin (ANG)	TTURHFP	ANGI_HUMAN	Inhibitor	[4]
Orexin (HCRT)	TTU5HJP	OREX_HUMAN	Inhibitor	[4]
Pancreatic alpha-amylase (AMY2A)	TTCGSZ4	AMYP_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4703).
2	Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem. 2006 Apr 1;78(7):2370-6. doi: 10.1021/ac051827k.
3	Pyroglutamic acid: throwing light on a lightly studied metabolite
4	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5	Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.